PL3086782T3 - Zoptymalizowana formulacja farmaceutyczna do leczenia zmian zapalnych przełyku - Google Patents
Zoptymalizowana formulacja farmaceutyczna do leczenia zmian zapalnych przełykuInfo
- Publication number
- PL3086782T3 PL3086782T3 PL14814872T PL14814872T PL3086782T3 PL 3086782 T3 PL3086782 T3 PL 3086782T3 PL 14814872 T PL14814872 T PL 14814872T PL 14814872 T PL14814872 T PL 14814872T PL 3086782 T3 PL3086782 T3 PL 3086782T3
- Authority
- PL
- Poland
- Prior art keywords
- optimised
- esophagus
- treatment
- inflammatory changes
- pharmaceutical formula
- Prior art date
Links
- 210000003238 esophagus Anatomy 0.000 title 1
- 230000002757 inflammatory effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13199278.6A EP2886108B2 (de) | 2013-12-23 | 2013-12-23 | Optimierte pharmazeutische Formulierung zur Behandlung von entzündlichen Veränderungen des Ösophagus |
| EP14814872.9A EP3086782B1 (de) | 2013-12-23 | 2014-12-18 | Optimierte pharmazeutische formulierung zur behandlung von entzündlichen veränderungen des ösophagus |
| PCT/EP2014/078391 WO2015097053A1 (de) | 2013-12-23 | 2014-12-18 | Optimierte pharmazeutische formulierung zur behandlung von entzündlichen veränderungen des ösophagus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3086782T3 true PL3086782T3 (pl) | 2019-03-29 |
Family
ID=49911300
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13199278.6T PL2886108T5 (pl) | 2013-12-23 | 2013-12-23 | Zoptymalizowana formulacja farmaceutyczna do leczenia zmian zapalnych przełyku |
| PL14814872T PL3086782T3 (pl) | 2013-12-23 | 2014-12-18 | Zoptymalizowana formulacja farmaceutyczna do leczenia zmian zapalnych przełyku |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13199278.6T PL2886108T5 (pl) | 2013-12-23 | 2013-12-23 | Zoptymalizowana formulacja farmaceutyczna do leczenia zmian zapalnych przełyku |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US9867780B2 (pl) |
| EP (2) | EP2886108B2 (pl) |
| JP (3) | JP6522626B2 (pl) |
| CN (1) | CN105848648B (pl) |
| AU (1) | AU2014372739B2 (pl) |
| CA (1) | CA2934009C (pl) |
| CY (2) | CY1121168T1 (pl) |
| DK (2) | DK2886108T4 (pl) |
| EA (1) | EA029166B1 (pl) |
| ES (2) | ES2716990T5 (pl) |
| FI (1) | FI2886108T4 (pl) |
| HR (2) | HRP20190677T4 (pl) |
| HU (2) | HUE042009T2 (pl) |
| IL (1) | IL246172B (pl) |
| LT (2) | LT2886108T (pl) |
| PL (2) | PL2886108T5 (pl) |
| PT (2) | PT2886108T (pl) |
| RS (2) | RS58543B2 (pl) |
| SI (2) | SI2886108T2 (pl) |
| TR (1) | TR201815823T4 (pl) |
| UA (1) | UA117162C2 (pl) |
| WO (1) | WO2015097053A1 (pl) |
| ZA (1) | ZA201604225B (pl) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150043548A (ko) | 2009-10-01 | 2015-04-22 | 앱탈리스 파마테크, 인코포레이티드 | 경구 투여용 코르티코스테로이드 조성물 |
| WO2015034678A2 (en) | 2013-09-06 | 2015-03-12 | Aptalis Pharmatech, Inc. | Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis |
| LT2886108T (lt) * | 2013-12-23 | 2019-03-25 | Dr. Falk Pharma Gmbh | Optimizuota farmacinė kompozicija, skirta stemplės uždegiminių pakitimų gydymui |
| TWI777515B (zh) | 2016-08-18 | 2022-09-11 | 美商愛戴爾製藥股份有限公司 | 治療嗜伊紅性食道炎之方法 |
| EP4233872B1 (en) | 2018-10-24 | 2025-07-02 | Ferring B.V. | Mucoadhesive pharmaceutical compositions of corticosteroids |
| US12691128B2 (en) | 2019-10-01 | 2026-07-28 | Ellodi Pharmaceuticals, L.P. | Methods of treating eosinophilic esophagitis and reducing candidiasis |
| EP4091615A1 (en) | 2021-05-20 | 2022-11-23 | Dr. Falk Pharma Gmbh | Orodispersible effervescent tablet comprising budesonide for use in the treatment of eosinophilic esophagitis |
| CN116869927B (zh) * | 2023-09-06 | 2023-11-10 | 中国医学科学院北京协和医院 | 一种用于治疗嗜酸性食管炎的食道温敏凝胶 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3937455A1 (de) * | 1989-11-10 | 1991-05-16 | Nordmark Arzneimittel Gmbh | Antacidatabletten |
| DE59106133D1 (de) * | 1990-10-19 | 1995-09-07 | Spirig Ag | Feste, schnell-lösliche Arzneimittelzubereitung enthaltend S-(Carboxymethyl)-L-Cystein und/oder N-Acetylcystein. |
| DE4332394A1 (de) | 1993-09-23 | 1995-03-30 | Falk Pharma Gmbh | Budesonid-Pellets mit kontrolliertem Freigabeprofil und Verfahren zu ihrer Herstellung |
| US5639475A (en) | 1995-02-03 | 1997-06-17 | Eurand America, Incorporated | Effervescent microcapsules |
| US5607697A (en) | 1995-06-07 | 1997-03-04 | Cima Labs, Incorporated | Taste masking microparticles for oral dosage forms |
| US5807578A (en) | 1995-11-22 | 1998-09-15 | Lab Pharmaceutical Research International Inc. | Fast-melt tablet and method of making same |
| US5807577A (en) | 1995-11-22 | 1998-09-15 | Lab Pharmaceutical Research International Inc. | Fast-melt tablet and method of making same |
| US6350470B1 (en) | 1998-04-29 | 2002-02-26 | Cima Labs Inc. | Effervescent drug delivery system for oral administration |
| FR2834893B1 (fr) * | 2002-01-23 | 2004-02-27 | Servier Lab | Composition pharmaceutique orodispersible de perindopril |
| US20030215502A1 (en) | 2002-03-20 | 2003-11-20 | Elan Pharma International Limited | Fast dissolving dosage forms having reduced friability |
| WO2004064810A1 (ja) † | 2003-01-21 | 2004-08-05 | Nippon Shinyaku Co., Ltd. | 口腔内速崩性錠剤 |
| SE0401031D0 (sv) | 2004-04-22 | 2004-04-22 | Duocort Ab | A new glucocorticoid replacement therapy |
| US20060013873A1 (en) | 2004-07-16 | 2006-01-19 | Chih-Chiang Yang | Bioadhesive dosage form of steroids |
| US20070020330A1 (en) † | 2004-11-24 | 2007-01-25 | Medpointe Healthcare Inc. | Compositions comprising azelastine and methods of use thereof |
| US20070071817A1 (en) | 2005-09-26 | 2007-03-29 | Phyzz, Inc. | Effervescent oral care compositions and method of use |
| US8679545B2 (en) * | 2005-11-12 | 2014-03-25 | The Regents Of The University Of California | Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract |
| US8324192B2 (en) | 2005-11-12 | 2012-12-04 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
| CA2642577A1 (en) | 2006-02-15 | 2007-08-23 | Tika Lakemedel Ab | Methods of manufacturing corticosteroid solutions |
| EP2572705B1 (en) | 2007-10-01 | 2017-09-13 | Laboratorios Lesvi, S.L. | Orodispersible tablets |
| DK3354276T3 (da) | 2007-11-13 | 2020-03-30 | Meritage Pharma Inc | Sammensætninger til behandlingen af gastrointestinal inflammation |
| US20090264392A1 (en) | 2008-04-21 | 2009-10-22 | Meritage Pharma, Inc. | Treating eosinophilic esophagitis |
| SI2151235T1 (sl) * | 2008-07-21 | 2011-04-29 | Falk Pharma Gmbh | Farmacevtska formulacija za zdravljenje zgornjega prebavnega trakta |
| EP2328558A2 (en) † | 2008-08-08 | 2011-06-08 | McNeil-PPC, Inc. | Use of sucralose as a granulating agent |
| EP2440210A4 (en) * | 2009-06-12 | 2014-01-29 | Meritage Pharma Inc | METHOD FOR THE TREATMENT OF STOMACH DARM DISEASES |
| LT2886108T (lt) | 2013-12-23 | 2019-03-25 | Dr. Falk Pharma Gmbh | Optimizuota farmacinė kompozicija, skirta stemplės uždegiminių pakitimų gydymui |
-
2013
- 2013-12-23 LT LTEP13199278.6T patent/LT2886108T/lt unknown
- 2013-12-23 HU HUE13199278A patent/HUE042009T2/hu unknown
- 2013-12-23 PL PL13199278.6T patent/PL2886108T5/pl unknown
- 2013-12-23 PT PT13199278T patent/PT2886108T/pt unknown
- 2013-12-23 RS RS20190347A patent/RS58543B2/sr unknown
- 2013-12-23 DK DK13199278.6T patent/DK2886108T4/da active
- 2013-12-23 SI SI201331391T patent/SI2886108T2/sl unknown
- 2013-12-23 EP EP13199278.6A patent/EP2886108B2/de active Active
- 2013-12-23 HR HRP20190677TT patent/HRP20190677T4/hr unknown
- 2013-12-23 FI FIEP13199278.6T patent/FI2886108T4/fi active
- 2013-12-23 ES ES13199278T patent/ES2716990T5/es active Active
-
2014
- 2014-12-18 LT LTEP14814872.9T patent/LT3086782T/lt unknown
- 2014-12-18 UA UAA201608055A patent/UA117162C2/uk unknown
- 2014-12-18 DK DK14814872.9T patent/DK3086782T3/en active
- 2014-12-18 US US15/107,735 patent/US9867780B2/en active Active
- 2014-12-18 TR TR2018/15823T patent/TR201815823T4/tr unknown
- 2014-12-18 AU AU2014372739A patent/AU2014372739B2/en active Active
- 2014-12-18 JP JP2016542264A patent/JP6522626B2/ja active Active
- 2014-12-18 CA CA2934009A patent/CA2934009C/en active Active
- 2014-12-18 HR HRP20181799TT patent/HRP20181799T1/hr unknown
- 2014-12-18 RS RS20181398A patent/RS58112B1/sr unknown
- 2014-12-18 PT PT14814872T patent/PT3086782T/pt unknown
- 2014-12-18 ES ES14814872.9T patent/ES2694331T3/es active Active
- 2014-12-18 EA EA201600497A patent/EA029166B1/ru not_active IP Right Cessation
- 2014-12-18 CN CN201480070548.1A patent/CN105848648B/zh active Active
- 2014-12-18 HU HUE14814872A patent/HUE041911T2/hu unknown
- 2014-12-18 EP EP14814872.9A patent/EP3086782B1/de active Active
- 2014-12-18 PL PL14814872T patent/PL3086782T3/pl unknown
- 2014-12-18 SI SI201430930T patent/SI3086782T1/sl unknown
- 2014-12-18 WO PCT/EP2014/078391 patent/WO2015097053A1/de not_active Ceased
-
2016
- 2016-06-13 IL IL246172A patent/IL246172B/en active IP Right Grant
- 2016-06-22 ZA ZA2016/04225A patent/ZA201604225B/en unknown
-
2017
- 2017-12-06 US US15/833,428 patent/US10369100B2/en active Active
-
2018
- 2018-11-21 CY CY20181101233T patent/CY1121168T1/el unknown
-
2019
- 2019-04-08 CY CY20191100386T patent/CY1121523T1/el unknown
- 2019-04-24 JP JP2019082802A patent/JP6757444B2/ja active Active
- 2019-06-17 US US16/442,756 patent/US10695291B2/en active Active
-
2020
- 2020-05-15 US US16/875,573 patent/US11382860B2/en active Active
- 2020-08-28 JP JP2020144070A patent/JP7009575B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL243976B (en) | kdm1a inhibitors for disease treatment | |
| SI3269716T1 (sl) | Nove spojine in farmacevtski sestavki le-teh za zdravljenje vnetnih motenj | |
| SI3086782T1 (sl) | Optimizirana farmacevtska formulacija za zdravljenje vnetnih sprememb ezofagusa | |
| EP2896352A4 (en) | ENDOSCOPE | |
| PL3062790T3 (pl) | Połączenia farmaceutyczne do leczenia raka | |
| ZA201603117B (en) | Withanolides useful for the treatment of neurodegenerative diseases | |
| IL242546A0 (en) | New compounds for cancer treatment | |
| ZA201507724B (en) | The treatment of inflammatory disorders | |
| EP3089984A4 (en) | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | |
| GB2528413B (en) | Inhibition of IL-2 production | |
| IL236870B (en) | History of hydroxystatin for the treatment of osteoarthritis | |
| PL3016948T3 (pl) | 2-acyloaminotiazole do leczenia nowotworów | |
| GB201306411D0 (en) | Treatment of inflammatory conditions | |
| IL241331B (en) | Delay of degenerative diseases | |
| GB201321628D0 (en) | Treatment of disease | |
| AP2015008905A0 (en) | Novel compounds for the treatment of cancer | |
| GB201314015D0 (en) | Novel compound useful for the treatment of degenerative and inflammatory diseases | |
| GB201315079D0 (en) | Novel compounds useful for the treatment of degenerative and inflammatory diseases | |
| GB201314016D0 (en) | Novel compounds useful for the treatment of degenerative and inflammatory diseases | |
| GB201303721D0 (en) | Compositions for treatment of sleep disorders | |
| AU2013900139A0 (en) | Device for the treatment of snoring |